Q-omics provides the consensus-scored THTPA profile across patient tissues and cancer cell-line models. THTPA expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, THTPA is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, THTPA RNA expression shows 19,566 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KIRC, and ACC as cancer lineages where THTPA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THTPA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THTPA survival associations across molecular data types. THTPA RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THTPA RNA expression–survival associations across cancer types. High THTPA expression shows unfavorable associations in UVM, but favorable associations in MESO, BRCA, KIRC, UCS and LGG. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for THTPA RNA expression.
This table summarizes THTPA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for THTPA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THTPA shows lower tumor expression in KIRC, THCA, KICH, KIRP and UCEC and higher tumor expression in LIHC. The KIRC box plot shows higher THTPA RNA expression in normal versus tumor tissue (log2 FC = −0.809, t-test p < 0.001).
This table shows molecular features associated with THTPA in patient tissues and cancer cell lines. In patient samples, THTPA shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, THTPA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
